Shares of MEDNAX, Inc. (NYSE:MD – Get Rating) have been assigned an average recommendation of “Hold” from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $26.29.
MD has been the subject of several recent research reports. StockNews.com cut MEDNAX from a “buy” rating to a “hold” rating in a research report on Monday, May 2nd. Zacks Investment Research cut MEDNAX from a “buy” rating to a “hold” rating and set a $25.00 price target for the company. in a research report on Wednesday, April 20th. Credit Suisse Group reduced their price target on MEDNAX from $32.00 to $31.00 and set an “outperform” rating for the company in a research report on Wednesday, February 23rd. TheStreet lowered MEDNAX from a “b-” rating to a “c+” rating in a research note on Wednesday, April 13th. Finally, Mizuho dropped their price objective on MEDNAX from $28.00 to $23.00 in a research note on Monday, May 2nd.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Maryland State Retirement & Pension System increased its stake in shares of MEDNAX by 1.5% during the fourth quarter. Maryland State Retirement & Pension System now owns 34,465 shares of the company’s stock worth $938,000 after purchasing an additional 506 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of MEDNAX by 0.9% during the fourth quarter. Thrivent Financial for Lutherans now owns 70,451 shares of the company’s stock worth $1,917,000 after purchasing an additional 609 shares during the period. Profund Advisors LLC increased its stake in shares of MEDNAX by 8.2% during the fourth quarter. Profund Advisors LLC now owns 9,308 shares of the company’s stock worth $253,000 after purchasing an additional 706 shares during the period. M&T Bank Corp increased its stake in shares of MEDNAX by 4.7% during the fourth quarter. M&T Bank Corp now owns 16,569 shares of the company’s stock worth $451,000 after purchasing an additional 739 shares during the period. Finally, Victory Capital Management Inc. increased its stake in MEDNAX by 2.5% during the 4th quarter. Victory Capital Management Inc. now owns 32,865 shares of the company’s stock worth $894,000 after acquiring an additional 807 shares during the period. Institutional investors own 95.68% of the company’s stock.
MEDNAX (NYSE:MD – Get Rating) last issued its quarterly earnings results on Thursday, April 28th. The company reported $0.29 EPS for the quarter, beating the consensus estimate of $0.23 by $0.06. MEDNAX had a return on equity of 15.64% and a net margin of 4.73%. The firm had revenue of $482.20 million during the quarter, compared to analysts’ expectations of $471.29 million. During the same period in the prior year, the firm posted $0.20 earnings per share. The business’s quarterly revenue was up 7.9% compared to the same quarter last year. Equities analysts expect that MEDNAX will post 1.75 EPS for the current year.
About MEDNAX (Get Rating)
MEDNAX, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
- Get a free copy of the StockNews.com research report on MEDNAX (MD)
- Affirm Stock Has Affirmed a Bottom
- Airbnb: Bold Competitive Threats & A New World of Travel
- Is RBC Bearings Rolling Into A Reversal?
- Should Dollar General or Dollar Tree Give Investors a Case of FOMO?
- Genesco Pops On Earnings But Don’t Expect A Rally
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.